+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a new oral cladribine formulation in adults with Generalized Myasthenia Gravis gMG. This Phase 3 clinical trial compares two doses of cladribine with a placebo and also studies the long-term safety, sustained effects, and need for retreatment of cladribine in people with gMG. Additionally, the study will examine how the body processes cladribine through a pharmacokinetic sub-study. Participants are randomly assigned to one of three groups placebo, low dose cladribine, or high dose cladribine. Each group receives two separate treatment courses orally, starting on Day 1 and again at Week 5 during the double-blind placebo-controlled period. After this, participants enter a blinded extension where those initially on placebo switch to cladribine doses, and those initially on cladribine receive placebo courses. If needed, participants may enter a retreatment period to receive additional cladribine or placebo doses based on clinical judgment. During the study, participants undergo regular assessments including changes in muscle weakness and daily living activities using specific scales like the MG-ADL. Safety is monitored through tracking adverse events, lab tests, vital signs, and heart monitoring. The study also includes in-depth interviews with a subset of participants to understand their treatment and study experience. The total study duration extends up to 144 weeks, allowing long-term follow-up and evaluation.

Age: 18Years +All GendersPhase 3
154 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of angiotensin II injection compared to placebo in adult patients with refractory distributive shock. This phase III, randomized, double-blind, placebo-controlled trial aims to improve blood pressure management in patients who continue to have low mean arterial pressure despite treatment with vasoactive drugs. The study involves patients aged 18 to 75 years who have received certain vasoactive medications and meet specific clinical criteria for refractory distributive shock. Participants will be randomly assigned to receive either angiotensin II injection or a placebo through a central vein. The dosage will be adjusted based on mean arterial pressure, with allowable doses ranging from 1.25 to 160 ngkgmin, and treatment duration up to 168 hours. Both groups receive background treatment with catecholamines and other vasopressors as needed. During the study, participants will be monitored for blood pressure response at various time points after drug administration, including 1, 2, and 3 hours. Additional assessments will include organ function scores, mortality at days 7 and 28, changes in vasoactive agent doses, blood lactate levels, heart rate, and recording of adverse events over 28 days. Patients must have central venous and arterial catheters for monitoring and are expected to remain in the study for at least 48 hours of treatment evaluation.

Age: 18Years +All GendersPhase 3
42 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of BR005-036C tablets compared to placebo in adults experiencing acute migraine attacks, including those with or without aura. This phase IIIII, multicenter, randomized, double-blind study aims to better understand how well BR005-036C works to relieve migraine symptoms and how it compares to placebo treatment. Participants are randomly assigned to take one of two doses of BR005-036C oral tablets or a matching placebo tablet. The study assesses the medications effects shortly after dosing, focusing on relief from pain and bothersome symptoms within two hours. The trial includes a treatment period with close monitoring for up to nine days after taking the study drug. During the study, participants will be monitored for migraine pain relief, freedom from symptoms, use of rescue medications, and functional ability after dosing. Researchers will track adverse events and other safety measures throughout the treatment period. The primary outcomes focus on pain freedom and symptom relief two hours after dosing, with additional assessments up to 48 hours. Participants involvement includes medication dosing and follow-up visits to assess their response and safety.

Age: 18Years +All GendersPhase 2Phase 3
83 locations